Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Phase 1

Recruiting

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Hematologic Malignancy
Recurrent Adult Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome

Interventions: Drug: Fludarabine Phosphate
Drug: Melphalan
Radiation: Intensity-Modulated Radiation Therapy
Radiation: Total Marrow Irradiation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Bone Marrow Transplantation
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-01-07

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT02333162

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of Unknown Primary
Adult Cholangiocarcinoma
Gallbladder Carcinoma
Malignant Gastrointestinal Neoplasm
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Gastric Adenocarcinoma
Stage III Ampulla of Vater Cancer
Stage III Pancreatic Cancer
Stage IIIA Gallbladder Cancer

Interventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Drug: Leucovorin Calcium
Drug: Irinotecan Hydrochloride
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-01-07

Last Posted Date: 2023-05-31

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT02333188

Locations: 🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸
Virginia Mason, Seattle, Washington, United States

and more 5 locations

Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer

Completed

Conditions: Free Tissue Flaps
Head and Neck Neoplasms

First Posted Date: 2015-01-06

Last Posted Date: 2023-04-18

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT02332161

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans

Not Applicable

Completed

Conditions: Substance Abuse

Interventions: Drug: methamphetamine
Drug: placebo

First Posted Date: 2014-12-23

Last Posted Date: 2018-07-26

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT02323048

Pre/Post Pilot Test of Video Module Education

Not Applicable

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease

Interventions: Behavioral: VME Group

First Posted Date: 2014-10-29

Last Posted Date: 2019-06-04

Lead Sponsor: University of Chicago

Target Recruit Count: 90

Registration Number: NCT02278237

Pilot Study of Novel Postpartum Educational Video Intervention

Not Applicable

Completed

Conditions: Language
Behavior
Communication

Interventions: Other: Safe Sleep for your Baby (SIDS) educational video
Other: TMW-Newborn Intervention video

First Posted Date: 2014-10-17

Last Posted Date: 2017-12-06

Lead Sponsor: University of Chicago

Target Recruit Count: 694

Registration Number: NCT02267265

Locations: 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

Phase 2

Active, not recruiting

Conditions: Human Papilloma Virus Infection
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVB Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: carboplatin
Radiation: radiation therapy
Other: laboratory biomarker analysis
Drug: paclitaxel
Procedure: quality-of-life assessment
Drug: fluorouracil
Drug: hydroxyurea
Drug: cisplatin

First Posted Date: 2014-10-07

Last Posted Date: 2023-09-18

Lead Sponsor: University of Chicago

Target Recruit Count: 62

Registration Number: NCT02258659

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Home Sleep and Metabolism

Not Applicable

Completed

Conditions: Overweight
Sleep

Interventions: Other: sleep

First Posted Date: 2014-10-01

Last Posted Date: 2021-02-05

Lead Sponsor: University of Chicago

Target Recruit Count: 210

Registration Number: NCT02253368

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Thirty Million Words Home Visiting

Not Applicable

Active, not recruiting

Conditions: Language Environments of Children of Low-socioeconomic Status

Interventions: Other: TMW Curriculum
Other: Nutrition Curriculum

First Posted Date: 2014-08-13

Last Posted Date: 2024-02-21

Lead Sponsor: University of Chicago

Target Recruit Count: 206

Registration Number: NCT02216032

Locations: 🇺🇸
Thirty Million Words® Initiative at the University of Chicago Medicine, Chicago, Illinois, United States

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1

Active, not recruiting

Conditions: Adult Grade III Lymphomatoid Granulomatosis
B-cell Chronic Lymphocytic Leukemia
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma
Contiguous Stage II Grade 3 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma

Interventions: Drug: lenalidomide
Drug: etoposide
Drug: prednisone
Drug: vincristine sulfate
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: rituximab
Other: quality-of-life assessment
Other: laboratory biomarker analysis

First Posted Date: 2014-08-12

Last Posted Date: 2023-04-28

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT02213913

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Illinois Cancer Care, Peoria, Illinois, United States

and more 3 locations

Home Terms & Conditions Privacy Policy